StockNews.AISignal intelligence
Spruce Biosciences, Inc. · NASDAQ · Healthcare
Browse public SPRB signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Spruce Biosciences halted tildacerfont trials for congenital adrenal hyperplasia. The CAHmelia-204 trial missed its primary efficacy endpoint. Tildacerfont showed a slight reduction in glucocorticoid dosage. Stock dropped 23.40% in premarket trading post-announcement. CEO states focus on conserving resources to maximize shareholder value.
View signal analysisSpruce Biosciences will halt investments in its genetic disorder drug due to failure in trials.
View signal analysis- SPRB reported quarterly loss of $0.28 per share, beating estimates and showing growth. - Revenues for SPRB of $2 million exceeded estimates by 79.55%. - Shares of SPRB have declined 71.6% year-to-date compared to S&P 500's gain. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis